Euroopan unioni -
suomi -
EMA (European Medicines Agency)
ranivisio
midas pharma gmbh - ranibitsumabi - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - silmätautien - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
bosentan ratiopharm 62.5 mg tabletti, kalvopäällysteinen
ratiopharm gmbh - bosentanum monohydricum - tabletti, kalvopäällysteinen - 62.5 mg - bosentaani
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
bosentan ratiopharm 125 mg tabletti, kalvopäällysteinen
ratiopharm gmbh - bosentanum monohydricum - tabletti, kalvopäällysteinen - 125 mg - bosentaani
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
vancomycin mip pharma 500 mg infuusiokuiva-aine, liuosta varten
mip pharma gmbh - vancomycin hydrochloride - infuusiokuiva-aine, liuosta varten - 500 mg - vankomysiini
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
vancomycin mip pharma 1000 mg infuusiokuiva-aine, liuosta varten
mip pharma gmbh - vancomycin hydrochloride - infuusiokuiva-aine, liuosta varten - 1000 mg - vankomysiini
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
vancosan 500 mg infuusiokuiva-aine, liuosta varten
mip pharma gmbh - vancomycin hydrochloride - infuusiokuiva-aine, liuosta varten - 500 mg - vankomysiini
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
vancosan 1000 mg infuusiokuiva-aine, liuosta varten
mip pharma gmbh - vancomycin hydrochloride - infuusiokuiva-aine, liuosta varten - 1000 mg - vankomysiini
Euroopan unioni -
suomi -
EMA (European Medicines Agency)
yesafili
viatris limited - aflibersepti - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - silmätautien - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.
Euroopan unioni -
suomi -
EMA (European Medicines Agency)
thiotepa riemser
esteve pharmaceuticals gmbh - tiotepa - hematopoietic stem cell transplantation; neoplasms - antineoplastiset aineet - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
asmasal clickhaler 95 mikrog/annos inhalaatiojauhe
celltech pharmaceuticals limited - salbutamoli sulfas - inhalaatiojauhe - 95 mikrog/annos - salbutamoli